NASDAQ
45.00USD
+2.09 (+4.87%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
2.6B
P/E
—
EPS
—
Beta
-1.42
52W range
15.8-94.9
Day range
42.79–45.75
Open
42.79
Prev close
42.91
Volume
1M
Avg volume
872.9K
Dividend
0.00
IPO
2023-02-03
https://www.youtube.com/watch?v=wmZXCu9-1jk · 6/13/2026+0.20
https://www.fool.com/coverage/filings/2026/05/24/this-biotech-is-up-60-a-top-healthcare-fund-just-bought-another-usd11-million/ · 5/24/2026+0.80
https://www.defenseworld.net/2026/04/04/structure-therapeutics-inc-sponsored-adr-nasdaqgpcr-given-consensus-rating-of-moderate-buy-by-brokerages-2.html · 4/4/2026+0.60
https://www.defenseworld.net/2026/04/04/dht-holdings-inc-nysedht-receives-average-rating-of-moderate-buy-from-analysts.html · 4/4/2026+0.60
https://www.fool.com/coverage/filings/2026/03/22/structure-therapeutics-slides-28-this-year-as-usd6-million-stake-emerges/ · 3/22/2026+0.30
https://seekingalpha.com/article/4871705-structure-therapeutics-the-dark-horse-has-taken-the-lead-but-is-it-enough · 2/18/2026+1.00
https://www.fool.com/coverage/filings/2026/02/17/structure-therapeutics-stock-up-187-in-one-year-as-fund-trims-usd8-million-from-stake/ · 2/17/2026+0.80
https://www.benzinga.com/news/health-care/26/01/49940898/structure-therapeutics-ceo-says-compounding-threat-looms-for-future-obesity-treatments · 1/15/2026+0.30
https://247wallst.com/investing/2025/12/18/stock-market-live-december-18-2025-sp-500-spy-soaring-on-micron-earnings/ · 12/18/2025+0.00
https://invezz.com/news/2025/12/08/structure-therapeutics-stock-whats-driving-sudden-103-jump-in-gpcr-shares/ · 12/8/2025+1.00
https://www.globenewswire.com/news-release/2025/12/08/3201469/0/en/Structure-Therapeutics-Reports-Positive-Topline-Data-from-ACCESS-Program-for-its-Once-Daily-Oral-Small-Molecule-GLP-1-Receptor-Agonist-Aleniglipron.html · 12/8/2025+1.00
Structure Therapeutics Inc., an international biopharmaceutical company currently in its clinical development phase, is committed to creating and providing groundbreaking oral therapies for various chronic diseases that lack adequate treatment options. The company's primary investigational drug, GSBR-1290, is an orally administered, biased small molecule agonist designed to target the glucagon-like-peptide-1 receptor (GLP-1R). This G-protein-coupled receptor (GPCR) is a recognized and validated therapeutic target for managing both type-2 diabetes mellitus and obesity. Furthermore, Structure Therapeutics is developing other oral small molecule treatments that act on different GPCRs, addressing pulmonary and cardiovascular conditions. For example, ANPA-0073 is a biased agonist aimed at the apelin receptor, a GPCR linked to diseases like idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension. Another compound in their pipeline is LTSE-2578, an oral small molecule that acts as a lysophosphatidic acid 1 receptor antagonist, also being explored for the treatment of IPF. Established in 2016, the company was formerly known as ShouTi Inc. and is headquartered in South San Francisco, California.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
